FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1989860636> ?p ?o ?g. }

• W1989860636 endingPage "1841" @default.
• W1989860636 startingPage "1832" @default.
• W1989860636 abstract "Denosumab is a monoclonal antibody to RANKL. In this randomized, placebo-controlled study of 412 postmenopausal women with low BMD, subcutaneous denosumab given every 3 or 6 mo was well tolerated, increased BMD, and decreased bone resorption markers for up to 24 mo. Continued study of denosumab is warranted in the treatment of low BMD in postmenopausal women.Denosumab is a fully human monoclonal antibody that inhibits RANKL, a key mediator of osteoclastogenesis and bone remodeling. This prespecified exploratory analysis evaluated the efficacy and safety of denosumab through 24 mo in the treatment of postmenopausal women with low BMD.Four hundred twelve postmenopausal women with lumbar spine BMD T-scores of -1.8 to -4.0 or femoral neck/total hip T-scores of -1.8 to -3.5 were randomly assigned to receive double-blind, subcutaneous injections of placebo; denosumab 6, 14, or 30 mg every 3 mo; denosumab 14, 60, 100, or 210 mg every 6 mo; or open-label oral alendronate 70 mg once weekly. Outcome measures included BMD at the lumbar spine, total hip, distal one-third radius, and total body; bone turnover markers; and safety.Denosumab increased BMD at all measured skeletal sites and decreased concentrations of bone turnover markers compared with placebo at 24 mo. At the lumbar spine, BMD increases with denosumab ranged from 4.13% to 8.89%. BMD changes with denosumab 30 mg every 3 mo and > or =60 mg every 6 mo were similar to, or in some cases greater than, with alendronate. The incidence of adverse events was similar in the placebo, denosumab, and alendronate treatment groups. Exposure-adjusted adverse events over 2 yr of treatment were similar to those reported during the first year of treatment.In these postmenopausal women with low BMD, treatment with denosumab for 2 yr was associated with sustained increases in BMD and reductions in bone resorption markers compared with placebo." @default.
• W1989860636 created "2016-06-24" @default.
• W1989860636 creator A5018073672 @default.
• W1989860636 creator A5018289238 @default.
• W1989860636 creator A5030361963 @default.
• W1989860636 creator A5037555787 @default.
• W1989860636 creator A5045290077 @default.
• W1989860636 creator A5048725197 @default.
• W1989860636 creator A5057538503 @default.
• W1989860636 creator A5060912313 @default.
• W1989860636 creator A5086493873 @default.
• W1989860636 date "2007-12-01" @default.
• W1989860636 modified "2023-10-09" @default.
• W1989860636 title "Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD" @default.
• W1989860636 cites W1550111394 @default.
• W1989860636 cites W1677043489 @default.
• W1989860636 cites W1978839856 @default.
• W1989860636 cites W1981384212 @default.
• W1989860636 cites W1984389510 @default.
• W1989860636 cites W1988611271 @default.
• W1989860636 cites W1998829944 @default.
• W1989860636 cites W1999077925 @default.
• W1989860636 cites W2000647744 @default.
• W1989860636 cites W2012229907 @default.
• W1989860636 cites W2039719308 @default.
• W1989860636 cites W2048299560 @default.
• W1989860636 cites W2048346627 @default.
• W1989860636 cites W2093252878 @default.
• W1989860636 cites W2096754770 @default.
• W1989860636 cites W2115012618 @default.
• W1989860636 cites W2117710877 @default.
• W1989860636 cites W2128843508 @default.
• W1989860636 cites W2133551420 @default.
• W1989860636 cites W2146217561 @default.
• W1989860636 cites W2169083990 @default.
• W1989860636 cites W2482202957 @default.
• W1989860636 cites W4254761345 @default.
• W1989860636 doi "https://doi.org/10.1359/jbmr.070809" @default.
• W1989860636 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17708711" @default.
• W1989860636 hasPublicationYear "2007" @default.
• W1989860636 type Work @default.
• W1989860636 sameAs 1989860636 @default.
• W1989860636 citedByCount "282" @default.
• W1989860636 countsByYear W19898606362012 @default.
• W1989860636 countsByYear W19898606362013 @default.
• W1989860636 countsByYear W19898606362014 @default.
• W1989860636 countsByYear W19898606362015 @default.
• W1989860636 countsByYear W19898606362016 @default.
• W1989860636 countsByYear W19898606362017 @default.
• W1989860636 countsByYear W19898606362018 @default.
• W1989860636 countsByYear W19898606362019 @default.
• W1989860636 countsByYear W19898606362020 @default.
• W1989860636 countsByYear W19898606362021 @default.
• W1989860636 countsByYear W19898606362022 @default.
• W1989860636 countsByYear W19898606362023 @default.
• W1989860636 crossrefType "journal-article" @default.
• W1989860636 hasAuthorship W1989860636A5018073672 @default.
• W1989860636 hasAuthorship W1989860636A5018289238 @default.
• W1989860636 hasAuthorship W1989860636A5030361963 @default.
• W1989860636 hasAuthorship W1989860636A5037555787 @default.
• W1989860636 hasAuthorship W1989860636A5045290077 @default.
• W1989860636 hasAuthorship W1989860636A5048725197 @default.
• W1989860636 hasAuthorship W1989860636A5057538503 @default.
• W1989860636 hasAuthorship W1989860636A5060912313 @default.
• W1989860636 hasAuthorship W1989860636A5086493873 @default.
• W1989860636 hasBestOaLocation W19898606361 @default.
• W1989860636 hasConcept C126322002 @default.
• W1989860636 hasConcept C126894567 @default.
• W1989860636 hasConcept C142724271 @default.
• W1989860636 hasConcept C170033053 @default.
• W1989860636 hasConcept C204787440 @default.
• W1989860636 hasConcept C27081682 @default.
• W1989860636 hasConcept C2775854910 @default.
• W1989860636 hasConcept C2776286101 @default.
• W1989860636 hasConcept C2776541429 @default.
• W1989860636 hasConcept C2776886416 @default.
• W1989860636 hasConcept C673006 @default.
• W1989860636 hasConcept C71924100 @default.
• W1989860636 hasConceptScore W1989860636C126322002 @default.
• W1989860636 hasConceptScore W1989860636C126894567 @default.
• W1989860636 hasConceptScore W1989860636C142724271 @default.
• W1989860636 hasConceptScore W1989860636C170033053 @default.
• W1989860636 hasConceptScore W1989860636C204787440 @default.
• W1989860636 hasConceptScore W1989860636C27081682 @default.
• W1989860636 hasConceptScore W1989860636C2775854910 @default.
• W1989860636 hasConceptScore W1989860636C2776286101 @default.
• W1989860636 hasConceptScore W1989860636C2776541429 @default.
• W1989860636 hasConceptScore W1989860636C2776886416 @default.
• W1989860636 hasConceptScore W1989860636C673006 @default.
• W1989860636 hasConceptScore W1989860636C71924100 @default.
• W1989860636 hasIssue "12" @default.
• W1989860636 hasLocation W19898606361 @default.
• W1989860636 hasLocation W19898606362 @default.
• W1989860636 hasOpenAccess W1989860636 @default.
• W1989860636 hasPrimaryLocation W19898606361 @default.
• W1989860636 hasRelatedWork W152247342 @default.
• W1989860636 hasRelatedWork W1978234349 @default.
• W1989860636 hasRelatedWork W2029733853 @default.

• next